Tauro-β-muricholic acid sodium

Tauro-β-muricholic Acid sodium (T-βMCA sodium), a endogenous metabolite , is a competitive and reversible farnesoid X receptor (FXR) antagonist, with an IC 50 of 40 μM In Vitro T-βMCA sodium inhibits FXR reporter activity in the CRC cell line HT29 (EC 50 ~10 μM). T-βMCA sodium dose-dependently increases WNT signaling in HT29 and HCT116 cells. T-βMCA sodium induces proliferation and DNA damage in Lgr5 + cells. MCE has not independently confirmed the accuracy of these methods. They are for reference only. In Vivo T-βMCA sodium (400 mg/kg; i.g.; twice a week; for 6 weeks) can effectively recapitulate the ability of HFD to promote CRC progression. T-βMCA sodium treatment also significantly increases levels of serum cytokines, including IFN-γ, IL-6, and IL-17. MCE has not independently confirmed the accuracy of these methods. They are for reference only. Animal Model: APCmin/+ miceDosage: 400 mg/kg Administration: Oral gavage; twice a week; for 6 weeks Result: Markedly decreased intestinal integrity and accelerated tumor growth in the intestine and colon. Form:Solid IC50& Target:IC50: 40 μM (FXR)

No numbering system information yet

No physical and chemical property information yet

No safety information yet

No production method and use information yet

No upstream information yet

No downstream information yet

No related product information yet